Seed funding for basic, translational, or clinical projects focused on thyroid cancer prevention, diagnosis, treatment, outcomes, or pathophysiology. Preference for early-stage investigators or new lines of inquiry needing pilot data.
Eligibility criteria:
-
Reside in the U.S. or Canada and be an AHNS member in good standing.
-
Eligible applicants: medical students (otolaryngology focus), otolaryngology residents, PhDs, or faculty in otolaryngology departments.
-
Preference: ≤10 years from terminal degree or fellowship, or established investigators starting a new direction.
-
Not eligible if the same project is already funded by a private or federal agency; if multiple awards are offered for the same project, only one may be accepted.
-
Required letters: department chair and principal scientific mentor (confirm time/space/resources and supervision).
-
IRB/IACUC approvals required prior to funding (or documentation of “pending” at submission).
Funding details:
-
Amount: up to $10,000 total.
-
Term: 1 year, non-renewable.
-
Allowable: research staff support, consultant/statistical fees, software/hardware, animals, lab supplies/services, and publication costs (not reprints).
-
Not allowed: PI salary.
-
Indirects: preferably waived; if charged, capped at 10% of direct costs with total costs ≤$10,000.
-
Equipment/supplies become property of the recipient institution.
-
Review by CORE Study Section; AHNS Council approves. Interim (6-month) and final (30-day) reports required; final financial report due within 90 days of project end.
Deadline:
-
Letter of Intent: December 15, 2025.
-
Full application: January 15, 2026 (by midnight ET).
-
Notifications: June 2026.
-
Earliest start: July 1, 2026; latest activation: January 1, 2027.
Where to go for further information:
- Submit via ProposalCentral.
- For questions, email [email protected].